Atara Biotherapeutics vs Evaxion A/S
ATRA and EVAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and EVAX compare
Evaxion A/S grew revenue faster over the last twelve months (125% versus −97.4% for Atara Biotherapeutics).
Evaxion A/S keeps more of each dollar of sales as profit, with a net margin of −102% compared with −369% at Atara Biotherapeutics.
Atara Biotherapeutics scores higher on the StockData Score (7 against 2 for Evaxion A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | EVAX |
|---|---|---|
| Size and price | ||
| Market cap | $82.6M | – |
| Share price | $8.23 | $2.91 |
| Change, 1 year | −33.1% | −54.4% |
| Change, 5 years | −98.2% | −99.0% |
| Beta (5Y) | 1.65 | 1.24 |
| Employees | 14 | 45 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.8× | – |
| Growth | ||
| Revenue growth (TTM) | −97.4% | 125% (better) |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Operating margin | −344% | −123% (better) |
| Net margin | −369% | −102% (better) |
| FCF margin | – | −88.2% |
| Financial health | ||
| Interest coverage | – | −2.3× |
| Current ratio | 1.72 | 5.06 (better) |
| Altman Z-score | −153.99 | – |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Buyback yield | −10.4% | – |
| Shareholder yield | −10.4% | – |
| Ownership | ||
| Held by institutions | 44.5% | 0.38% |
| Held by insiders | 55.5% | 3.5% |
| Insider net buying, 12 months | $2.0M | – |
| Short interest, % of float | 6.6% | – |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- EVAX stock overview
- EVAX income statement
- EVAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.